The Wisconsin Alzheimer's Disease Research Center (ADRC) will build upon the remarkable strengths of the University of Wisconsin (UW) in neuroscience research to provide state-of-the-art resources, infrastructure, and expertise in Alzheimer's disease (AD) and related illnesses. With the major focus on preclinical and early diagnosis and progression of AD, the Wisconsin ADRC will expand the scientific objectives of the Wisconsin Registry for Alzheimer's Prevention (WRAP) and significantly enhance care of Wisconsin residents suffering from the devastations of AD. Comprised of six Cores (i.e., Administrative, Clinical, Data Management and Biostatistics, Neuropathology and Biomarkers, Education and Transfer and the Minority Recruitment Satellite Program), the ADRC builds upon the highly successful UW research program in AD and several recent convergent developments. These developments include a new focus of the UW leadership on AD, substantial institutional and state financial commitment to AD research, presence of several renowned programs in neuroscience on the UW campus, outstanding UW clinical programs, an extensive statewide network of dementia diagnostic clinics, access to minority, low-income and rural populations through the Minority Recruitment Satellite Program (MRSP), acknowledged status of several UW investigators in AD research, and close collaborations between numerous UW centers and institutes in aging and neuroscience research. Among others, these centers and institutes include the Wisconsin Alzheimer's Institute, the UW Waisman Center, the UW Waisman Laboratory for Brain Imaging and Behavior, the NIH/CTSA-funded Institute for Clinical and Translational Research (ICTR), the Institute on Aging, the Madison Veterans Affairs (VA) Geriatric Research, Education and Clinical Center (GRECC), the National Primate Research Center, the Biotechnology Center, the Genome Center, and the Clinical and Translational Research Core (formerly known as the UW GCRC). Given the access to outstanding resources and expertise, the Wisconsin ADRC is well poised to make novel contributions to the field of AD research and provide outstanding clinical care to patients suffering from the devastations of the disease.

Public Health Relevance

The major focus of the Wisconsin ADRC is to identify novel diagnostic tests and potential therapies for the prevention of Alzheimer's disease at a stage when patients have no clinical symptoms (preclinical stage). It is anticipated that such therapies will help reduce the number of individuals suffering from Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG033514-04
Application #
8248238
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Program Officer
Phelps, Creighton H
Project Start
2009-05-01
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
4
Fiscal Year
2012
Total Cost
$1,259,432
Indirect Cost
$410,384
Name
University of Wisconsin Madison
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-9
Melah, Kelsey E; Lu, Sharon Yuan-Fu; Hoscheidt, Siobhan M et al. (2016) Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. J Alzheimers Dis 50:873-86
Rivera-Rivera, Leonardo A; Turski, Patrick; Johnson, Kevin M et al. (2016) 4D flow MRI for intracranial hemodynamics assessment in Alzheimer's disease. J Cereb Blood Flow Metab 36:1718-1730
Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-21
Betthauser, Tobey; Lao, Patrick J; Murali, Dhanabalan et al. (2016) In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317. J Nucl Med :
Mukherjee, Jogeshwar; Bajwa, Alisha K; Wooten, Dustin W et al. (2016) Comparative assessment of (18) F-Mefway as a serotonin 5-HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humans. J Comp Neurol 524:1457-71
Kim, Won Hwa; Hwang, Seong Jae; Adluru, Nagesh et al. (2016) Adaptive Signal Recovery on Graphs via Harmonic Analysis for Experimental Design in Neuroimaging. Comput Vis ECCV 9910:188-205
Gordon, Jeremy W; Niles, David J; Adamson, Erin B et al. (2016) Application of flow sensitive gradients for improved measures of metabolism using hyperpolarized (13) c MRI. Magn Reson Med 75:1242-8
White, Matthew T; Shaw, Leslie M; Xie, Sharon X et al. (2016) Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease. J Alzheimers Dis 51:463-70
Martin, Stephen A; DeMuth, Tyler M; Miller, Karl N et al. (2016) Regional metabolic heterogeneity of the hippocampus is nonuniformly impacted by age and caloric restriction. Aging Cell 15:100-10

Showing the most recent 10 out of 211 publications